Judith A. Dunn's most recent trade in Climb Bio Inc. was a trade of 40,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 4, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Climb Bio Inc. | Judith A. Dunn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2025 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Climb Bio Inc. | Judith A. Dunn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2024 | 10,000 | 10,000 | - | - | Stock Option (Right To Buy) | |
| Climb Bio Inc. | Judith A. Dunn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 10,000 | 10,000 | - | - | Stock Option (Right To Buy) | |
| Climb Bio Inc. | Judith A. Dunn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2022 | 10,000 | 10,000 | - | - | Stock Option (Right To Buy) | |
| Fulcrum Therapeutics Inc | Judith A. Dunn | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2022 | 140,890 | 140,890 | - | - | Stock Option (right to buy) | |
| Fulcrum Therapeutics Inc | Judith A. Dunn | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 215,000 | 215,000 | - | - | Stock Option (right to buy) | |
| Seelos Therapeutics Inc | Judith A. Dunn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2021 | 16,000 | 16,000 | - | - | Stock Option (right to buy) |